How to Monitor Viloxazine ER Safety in Adults With ADHD
How should clinicians monitor safety after starting viloxazine ER in adults with ADHD and comorbid depression and/or anxiety symptoms?
In this comorbid adult ADHD population, viloxazine ER was generally well tolerated, but adverse effects were common and some events led to discontinuation. The study provides a practical monitoring framework centered on early suicidality assessment, adverse-effect review, and serial vital signs during the first 14 weeks of treatment.
-
Assess baseline safety before treatment
Before and during treatment, the study tracked systolic and diastolic blood pressure, pulse rate, and body weight. Suicidal ideation and behavior were also assessed using the Columbia-Suicide Severity Rating Scale at all televisits.
-
Plan early follow-up with suicidality review
Monitor closely early in treatment because 5 participants (3.1%) reported treatment-emergent adverse events of suicidal ideation and 2 serious, treatment-related cases were reported on day 3 of treatment. In the study, C-SSRS was administered at all televisits, and no suicidal behavior was reported during treatment.
-
Ask specifically about common adverse effects
The most common adverse events occurring in at least 5% of participants were nausea, insomnia, constipation, headache, fatigue, somnolence, decreased appetite, migraine, and dry mouth. Most treatment-emergent adverse events were mild to moderate, but 14.9% of participants discontinued treatment because of adverse events.
-
Watch for adverse effects that commonly lead to discontinuation
The adverse events leading to discontinuation in 3 or more participants were insomnia, nausea, decreased appetite, migraine, somnolence, dizziness, and suicidal ideation. If these emerge, reassess tolerability promptly because these were the events most often associated with stopping treatment.
-
Repeat blood pressure and pulse checks during treatment
The study found modest mean increases in systolic blood pressure, diastolic blood pressure, and pulse rate at all visits. By week 14/end of study, 20.0% had a greater than 15 mm Hg increase in systolic blood pressure, 13.3% had a greater than 15 mm Hg increase in diastolic blood pressure, and 10.2% had a greater than 20 beats per minute increase in pulse rate.
-
Include weight in ongoing monitoring
Body weight was followed as part of safety assessment, and the study observed a mean decrease in body weight at all visits. This is worth tracking during follow-up alongside appetite-related adverse effects such as decreased appetite.
-
Use extra caution in patients with greater medication burden
Participants with treatment-related adverse events that were severe, serious, or led to withdrawal had a higher mean number of baseline concomitant medications than those without such events, 3.4 versus 2.3. This does not establish causality, but it supports closer monitoring when viloxazine ER is used in the setting of polypharmacy.
Clinical Considerations
- Safety findings come from an open-label study and should be interpreted descriptively rather than as confirmatory estimates.
- The article states that further analysis is needed to determine whether adverse events were influenced by concomitant medication patterns, medical comorbidities, or cannabis use.
- Viloxazine ER was generally well tolerated among participants with and without stimulant use, but the impact of specific concomitant medication patterns was not yet evaluated.
- The decentralized design may limit consistency of some remotely collected assessments.
Bottom Line
After starting viloxazine ER in adults with ADHD and comorbid mood or anxiety symptoms, monitor early for suicidal ideation, ask directly about insomnia and nausea and other common adverse effects, and repeat blood pressure, pulse, and weight checks during treatment.
